In a changing healthcare landscape, delivering value requires true vision.
Adamis is currently developing products in the large respiratory and allergy markets. Adamis will pursue 505 (b) (2) regulatory approval filings whenever possible in order to minimize costs and shorten the time to market. The focus is to create high quality, lower-cost therapeutic alternatives to existing treatments. The company’s specialty pharmaceutical pipeline has several inhaled products for the treatment of asthma and chronic obstructive pulmonary disease (COPD) that include a new platform Taper Dry Powder Inhaler (DPI) technology that was acquired from 3M (NYSE:MMM). Adamis intends to pursue other products using this Taper DPI patented platform technology.
|Specialty Pharmaceuticals1||Potential Indication||Phase 1||Phase 2||Phase 3||NDA|
|APC-6000- Naloxone Injection||Opioid Overdose|
Sublingual Disintegrating Tablet
|Metered Dose Inhalers|
|APC-1000- HFA Inhaled Oral Steroid||Asthma/COPD|
|Dry Powder Inhaler Platform|
|APC-4000- Fluticasone DPI2||Asthma/COPD|
1 Represents the next development/regulatory stage Adamis intends to pursue 2 Proof of concept study is anticipated